Bioadaptives Inc Quick Ratio (BDPT) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Bioadaptives Inc   (BDPT)

Bioadaptives Inc 's Quick Ratio

BDPT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth




Within Major Pharmaceutical Preparations industry Bioadaptives Inc booked the highest Quick Ratio than Bioadaptives Inc in the second quarter 2026. While total ranking remained the same in the Q2 2026 compared to the first quarter 2026 at no. .

Explain Quick Ratio?
How much Cash & cash equivalents BDPT´s has?
What are BDPT´s Current Liabilities?




BDPT Quick Ratio (Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
(Jun 30 2025)
Q2
Y / Y Current Liabilities Change 45.5 % 35.12 % 36.52 % -14.16 % -27.07 %
Y / Y Cash & cash equivalent Change - 0 % 0 % 0 % 0 %
Quick Ratio MRQ - 0 0 0 0
BDPT's Total Ranking # # # # #
Seq. Current Liabilities Change -9.85 % -3.56 % 48.21 % 12.91 % -16.28 %
Seq. Cash & cash equivalent Change - 0 % 0 % 0 % 0 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Quick Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Bioadaptives Inc 's Current Liabilities $ 2 Millions Visit BDPT's Balance sheet
Bioadaptives Inc 's Cash & cash equivalent $ 0 Millions Visit BDPT's Balance sheet
Source of BDPT's Sales Visit BDPT's Sales by Geography


Cumulative Bioadaptives Inc 's Quick Ratio

BDPT's Quick Ratio for the trailling 12 Months

BDPT Quick Ratio

(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
(Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 23.99 % 6.06 % -4.39 % -13.16 % -4.74 %
Y / Y Cash & cash equivalent TTM Growth -25 % 0 % 0 % 0 % 33.14 %
Quick Ratio TTM 0 0 0 0 0
Total Ranking TTM # 4148 # 4155 # 3194 # 3449 # 2811
Seq. Current Liabilities TTM Growth 8.4 % 8.4 % 9.84 % -3.93 % -7.27 %
Seq. Cash & cash equivalent TTM Growth -25 % 0 % 0 % 0 % 0 %


On the trailing twelve months basis In Spite of the decrease in Current Liabilities in the Q2 2026 to $2.05 millions, cumulative Quick Ratio